The most recent findings have been published from the TRACK-HD study, designed to create an unprecedentedly detailed map of changes in prodromal and early Huntington’s disease.
The latest findings from the TRACK-HD study are published in The Lancet Neurology and could be used to assess whether potential new treatments are slowing the disease up to 10 years before the development of noticeable symptoms.
Currently, the effectiveness of a new drug is decided by its ability to treat symptoms," says lead author Professor Sarah Tabrizi. "These new tests could be used in future preventative drug trials in individuals who are gene positive for HD but are not yet showing overt motor symptoms.
"These people have the most to gain by initiating treatment early to delay the start of these overt symptoms and give them a high quality of life for a longer period of time."
Read Francis Walkerseditorial in The Lancet Neurology.
Direct link to study results available at the link below: